Indeed these cancer treatments are, associated with a higher incidence of all-grade mucositis compared to other EGFR-TKi (40% vs. 15% of all-grade, 8.7 vs. 1% of grade ≥ 3) [43] or to anti-EGFR monoclonal antibodies therapy [32]. This evidence concerns the gene EGFR and cancer.